STRO

STRO

USD

Sutro Biopharma Inc. Common Stock

$0.903-0.337 (-27.210%)

即時價格

Healthcare
生物科技
美國

價格圖表

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$1.240

最高

$1.240

最低

$0.832

交易量

0.04M

公司基本面

市值

108.9M

行業

生物科技

國家

United States

交易統計

平均交易量

1.76M

交易所

NGM

貨幣

USD

52週範圍

最低 $0.52當前 $0.903最高 $5.17

相關新聞

Analyst Upgrades

HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2

HC Wainwright & Co. analyst Andrew Fein downgrades Sutro Biopharma from Buy to Neutral and lowers the price target from $12 to $2.

查看更多
HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
GlobeNewswire

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

SOUTH SAN FRANCISCO, Calif., March 15, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs),

查看更多
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Analyst Upgrades

Citizens Capital Markets Downgrades Sutro Biopharma to Market Perform

Citizens Capital Markets analyst Reni Benjamin downgrades Sutro Biopharma from Market Outperform to Market Perform.

查看更多
Citizens Capital Markets Downgrades Sutro Biopharma to Market Perform
Analyst Upgrades

Wedbush Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2

Wedbush analyst David Nierengarten downgrades Sutro Biopharma from Outperform to Neutral and lowers the price target from $8 to $2.

查看更多
Wedbush Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2
Analyst Upgrades

B of A Securities Downgrades Sutro Biopharma to Underperform, Lowers Price Target to $1

B of A Securities analyst Tazeen Ahmad downgrades Sutro Biopharma from Buy to Underperform and lowers the price target from $11 to $1.

查看更多
B of A Securities Downgrades Sutro Biopharma to Underperform, Lowers Price Target to $1
GlobeNewswire

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

– Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable

GlobeNewswire

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug